Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 7.08TCr 6.22TCr 5.8TCr 5.33TCr 9.97TCr 6,77700Cr 10TCr 69TCr 27TCr 3,35300Cr 27TCr 26TCr 11,59300Cr P/E 2026 *
18.4x
P/E 2027 * 14.6x
Enterprise Value 6.29TCr 5.53TCr 5.16TCr 4.74TCr 8.87TCr 6,02800Cr 9.09TCr 61TCr 24TCr 2,98300Cr 24TCr 23TCr 10,31100Cr EV / Sales 2026 *
3.96x
EV / Sales 2027 * 3.42x
Free-Float
72.33%
Yield 2026 *
0.56%
Yield 2027 * 0.64%
1 day+1.49%
1 week+6.79%
Current month+11.53%
1 month+10.07%
3 months+1.32%
6 months-7.21%
Current year-9.90%
1 week 654.05
Extreme 654.05
702.6
1 month 623.89
Extreme 623.89
702.6
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
02/07/26 Sell

Director

-200 0.0002%
19/02/26 Fiscal year

Director

4,914 0.0048%
09/02/26 Fiscal year

SVP Controller

4,036 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%+6.79%+24.59%-6.79% 7.08TCr
-14.27%-11.60%+15.86%+166.77% 5.44TCr
-4.52%+47.90%+47.90%+47.90% 4.72TCr
-0.11%+10.52%-52.81%-52.36% 4.25TCr
-1.39%+5.81%+63.59%-21.11% 3.09TCr
-1.90%+9.77%+64.26%+101.46% 2.58TCr
+0.55%-6.16%+66.84%-54.08% 2.16TCr
-1.78%-3.24%-10.51%+154.62% 1.99TCr
-3.56%+1.06%+80.35%+142.71% 1.63TCr
-0.36%+3.36%+69.46%+130.00% 1.69TCr
Average -2.68%+3.56%+36.95%+60.91% 3.46TCr
Weighted average by Cap. -3.15%+4.78%+28.77%+49.15%

Financials

2026 *2027 *
Net sales 1.59TCr 1.4TCr 1.3TCr 1.2TCr 2.24TCr 1,52100Cr 2.29TCr 15TCr 6.04TCr 75TCr 5.96TCr 5.83TCr 2,60300Cr 1.76TCr 1.55TCr 1.44TCr 1.33TCr 2.48TCr 1,68700Cr 2.54TCr 17TCr 6.7TCr 83TCr 6.61TCr 6.47TCr 2,88700Cr
Net income 399.04Cr 350.64Cr 327.3Cr 300.37Cr 562.28Cr 38TCr 576.14Cr 3.88TCr 1.52TCr 19TCr 1.5TCr 1.47TCr 65TCr 506.34Cr 444.92Cr 415.3Cr 381.14Cr 713.46Cr 48TCr 731.05Cr 4.92TCr 1.93TCr 24TCr 1.9TCr 1.86TCr 83TCr
Net Debt -782.28Cr -687.39Cr -641.63Cr -588.84Cr -1.1TCr -75TCr -1.13TCr -7.61TCr -2.98TCr -37TCr -2.94TCr -2.87TCr -1,28200Cr -1.05TCr -923.77Cr -862.27Cr -791.34Cr -1.48TCr -1,00700Cr -1.52TCr -10TCr -4TCr -50TCr -3.95TCr -3.86TCr -1,72300Cr
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
30/26/30 $695.42 +0.03% 10,22,421
28/26/28 $695.18 +4.20% 9,00,408
27/26/27 $667.17 +1.70% 6,50,984
24/26/24 $656.01 +0.63% 7,08,392
23/26/23 $651.91 +0.11% 11,29,411
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
695.42USD
Average target price
816.80USD
Spread / Average Target
+17.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock